USPTO serial 79093385
TG THROMBOGENICS
Reviewed by CopyMark Law Group
Reg. 4047607Status 709
- Filing date
- Status date
- Registration date
- Nov 1, 2011
- Examiner
- RUTLAND, BARBARA A
- Law office
- —
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TG THROMBOGENICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Thomas J. Mango
Thomas J. Mango Cantor Colburn LLP20 Church Street22nd FloorHartford, CT 06103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations and substances for use in the manufacture of pharmaceuticals | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical preparations for treatment of diseases and disorders, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; veterinary preparations for treatment of diseases and disorders in mammalians, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; sanitary preparations for medical purposes; dietetic foods adapted for medical use, food for babies; medical plasters; material for stopping teeth, dental wax; disinfectants for medical instruments, for hygienic purposes, and for use in medical surgery procedures; preparations for destroying vermin; fungicides, herbicides; biopharmaceutical preparations, namely, anticoagulants, anti angiogenic drugs, anticancer drugs, cardiovascular drugs, protease enzymes, protease inhibitors, antibodies, plasmins, truncated plasmins, microplasmins, plasminogens, truncated plasminogens, microplasminogens, plasminogen activators, staphylokinases for the treatment diseases and disorders, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; diagnostic medical reagents, chemicals and biological materials, namely, antigen and diagnostic kits consisting primarily of monoclonal and/or polyclonal antibodies, buffers, and reagents for medical laboratory use in disease testing | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services, namely, scientific research and design of new products in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder detection, in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder prevention, and in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder treatment; industrial analysis and product research services in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder detection, in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder prevention and in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder treatment; pharmaceutical, biopharmaceutical, medical, biomedical, biological, biochemical, toxicological and clinical research and product development of diagnostic tests and kits, biopharmaceutical preparations and drugs, and medicines; biopharmaceutical product evaluation; biological, biochemical, pharmaceutical, medical, toxicological and clinical research, scientific research for medical purposes in the treatment of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer diseases and disorders; development services in the field of new biopharmaceutical drugs, preparations and medicines for ophthalmic, vascular and cancer pathologies | SECTION 71 - CANCELLED | — |
| 044 | Medical services; veterinary services; medical, veterinary and pharmaceutical advisory and consultancy services; medical services, namely, therapeutic, prognostic and diagnostic testing services | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ThromboGenics NV
- Other trademarks owned by Oxurion NV
- Other trademarks owned by ThromboGenics NV
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named TG THROMBOGENICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 26, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 8, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 11, 2023 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Mar 1, 2023 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Mar 1, 2023 | INPC | INVALIDATION PROCESSED | — |
| Jan 13, 2023 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 13, 2022 | C71T | CANCELLED SECTION 71 | — |
| Dec 17, 2020 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Nov 1, 2020 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Jun 13, 2019 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Mar 8, 2019 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Jan 26, 2019 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Jan 26, 2019 | INPC | INVALIDATION PROCESSED | — |
| Jan 11, 2019 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Sep 28, 2018 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 11, 2018 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| May 11, 2018 | 71.P | REGISTERED - PARTIAL SEC 71 ACCEPTED | — |
| May 11, 2018 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 1, 2018 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Jul 28, 2012 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 8, 2012 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 8, 2012 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 1, 2012 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 1, 2011 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 16, 2011 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 27, 2011 | NPUB | NOTICE OF PUBLICATION | — |
| Jul 13, 2011 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 12, 2011 | ALIE | ASSIGNED TO LIE | — |
| Jun 18, 2011 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 17, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 17, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 17, 2011 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 9, 2011 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 22, 2011 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 22, 2011 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 19, 2011 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 18, 2011 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 12, 2011 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 8, 2011 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 8, 2011 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 4, 2011 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Mar 3, 2011 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |